ATRA earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Hold, P/E -12.31. Updated 2026-07-23.
Atara Biotherapeutics (ATRA) Research Hub
Atara Biotherapeutics (ATRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 9.38 USD (-5.35%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -12.31, market cap 0.08B. This hub links to the full technical, earnings and options research available for ATRA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 9.38 USD (-5.35%) |
| 52-week range | 7.39 USD – 12 USD |
| Trend regime | Range |
| 14-day RSI | 58.6 (Bullish) |
| Trailing P/E | -12.31 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for ATRA
Covered Call on ATRA: how it works, illustrative setup around the real 9.38 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ATRA: how it works, illustrative setup around the real 9.38 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ATRA: how it works, illustrative setup around the real 9.38 USD price, max profit/loss, breakeven and when to use it. Educational.
ATRA technical analysis: range, last 9.38 USD, RSI 58.6, 52w range 7.39 USD–12 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ATRA in?
Atara Biotherapeutics (ATRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ATRA in an uptrend or downtrend?
As of 2026-09-11, ATRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ATRA's trailing P/E ratio?
ATRA's trailing P/E is -12.31, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does ATRA next report earnings?
ATRA is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.315 USD.